Resumen de acción MANGALAM
Mangalam Drugs & Organics Limited fabrica y vende principios activos farmacéuticos (API) y productos intermedios en la India.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Competidores de Mangalam Drugs & Organics Limited
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | ₹101.30 |
| 52 Week High | ₹132.45 |
| 52 Week Low | ₹90.80 |
| Beta | 0.73 |
| 1 Month Change | -0.59% |
| 3 Month Change | -4.84% |
| 1 Year Change | -10.16% |
| 3 Year Change | -24.18% |
| 5 Year Change | 108.87% |
| Change since IPO | 744.17% |
Noticias y actualizaciones recientes
Little Excitement Around Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues As Shares Take 25% Pounding
Mar 28
Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Shares Lagging The Industry But So Is The Business
Feb 07Recent updates
Little Excitement Around Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues As Shares Take 25% Pounding
Mar 28Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Shares Lagging The Industry But So Is The Business
Feb 07Estimating The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)
Oct 20Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?
Mar 29These 4 Measures Indicate That Mangalam Drugs & Organics (NSE:MANGALAM) Is Using Debt Extensively
May 31A Look At The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)
Apr 06We Think Mangalam Drugs & Organics (NSE:MANGALAM) Is Taking Some Risk With Its Debt
Jan 03Here's Why Mangalam Drugs & Organics (NSE:MANGALAM) Can Manage Its Debt Responsibly
May 23Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?
Jan 04Do Its Financials Have Any Role To Play In Driving Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Stock Up Recently?
Nov 12
A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)
Sep 20Does Mangalam Drugs & Organics's (NSE:MANGALAM) Statutory Profit Adequately Reflect Its Underlying Profit?
Aug 05We Think Mangalam Drugs & Organics (NSE:MANGALAM) Can Stay On Top Of Its Debt
Jul 01Rentabilidad de los accionistas
| MANGALAM | IN Pharmaceuticals | Mercado IN | |
|---|---|---|---|
| 7D | 0.6% | 0.8% | 0.5% |
| 1Y | -10.2% | 58.6% | 44.7% |
Rentabilidad vs. Industria: MANGALAM obtuvo unos resultados inferiores a los del sector Indian Pharmaceuticals , que el año pasado arrojó un rendimiento del 56.7%.
Rentabilidad vs. Mercado: MANGALAM obtuvo unos resultados inferiores a los del mercado Indian, que fue del 46.4% el año pasado.
Volatilidad de los precios
| MANGALAM volatility | |
|---|---|
| MANGALAM Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in IN Market | 10.0% |
| 10% least volatile stocks in IN Market | 4.2% |
Precio estable de las acciones: El precio de las acciones de MANGALAM ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de MANGALAM (8%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1972 | 523 | Govardhan Dhoot | www.mangalamdrugs.com |
Mangalam Drugs & Organics Limited fabrica y vende principios activos farmacéuticos (API) y productos intermedios en la India. Ofrece una gama de productos API, que incluyen Aciclovir, Amodiaquina, Arteméter, Artesunato, Sulfato de Atazanavir, Fumarato de Bisoprolol, Fosfato de Cloroquina, Dihidroartemisinina y Dolutegravir Sódico; Efavirenz, Emtricitabina, Furosemida, Sulfato de Hidroxicloroquina, Lumefantrina y Nimesulida; Nitrofurantoína anhidra y monohidrato; Primaquina y fosfato de piperaquina; Pregabalina, pirimetamina, tetrafosfato de pironaridina y sulfadoxina; y hemifumarato y fumarato de disoproxilo de alafenamida de tenofovir. La empresa también ofrece productos intermedios que comprenden 2-Dibutilamino-1-(2,7-dicloro-9H-fluorina-4-il)-etanol; 4,6-Dicloro-5-metoxi pirimidina; 4,7 Dicloroquinolina; Ortofenoxi metano sulfonanilida; y Tenofovir Alafenamida Base y Disoproxil Base.
Resumen de fundamentos de Mangalam Drugs & Organics Limited
| Estadísticas fundamentales de MANGALAM | |
|---|---|
| Capitalización bursátil | ₹1.60b |
| Beneficios(TTM) | -₹169.87m |
| Ingresos (TTM) | ₹3.59b |
0.4x
Ratio precio-ventas (PS)-9.4x
Ratio precio-beneficio (PE)¿Está MANGALAM sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de MANGALAM | |
|---|---|
| Ingresos | ₹3.59b |
| Coste de los ingresos | ₹2.41b |
| Beneficio bruto | ₹1.19b |
| Otros gastos | ₹1.36b |
| Beneficios | -₹169.87m |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
May 30, 2024
| Beneficios por acción (BPA) | -10.73 |
| Margen bruto | 33.09% |
| Margen de beneficio neto | -4.73% |
| Ratio deuda/patrimonio | 71.4% |
¿Cómo se ha desempeñado MANGALAM a largo plazo?
Ver rendimiento histórico y comparativa